| scholarly article | Q13442814 |
| P433 | issue | 30 | |
| P921 | main subject | position paper | Q7233193 |
| P304 | page(s) | 349-364 | |
| P577 | publication date | 2016-07-01 | |
| P1433 | published in | Weekly Epidemiological Record | Q26842229 |
| P1476 | title | Dengue vaccine: WHO position paper – July 2016 | |
| P478 | volume | 91 |
| Q29572620 | A decade of arboviral activity—Lessons learned from the trenches |
| Q41930017 | A lethal model of disseminated dengue virus type 1 infection in AG129 mice |
| Q64061037 | A novel interaction between dengue virus nonstructural protein 1 and the NS4A-2K-4B precursor is required for viral RNA replication but not for formation of the membranous replication organelle |
| Q55160432 | Adverse events of vaccines and the consequences of non-vaccination: a critical review. |
| Q59137507 | Baseline Characterization of Dengue Epidemiology in Yogyakarta City, Indonesia, before a Randomized Controlled Trial of for Arboviral Disease Control |
| Q92689558 | Broad dengue neutralization in mosquitoes expressing an engineered antibody |
| Q63246670 | Burden of dengue among febrile patients at the time of chikungunya introduction in Piedecuesta, Colombia |
| Q90249174 | Cause and consequence of loss in vaccine trust |
| Q52662743 | Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines. |
| Q38157543 | Conditions for success of engineered underdominance gene drive systems. |
| Q37619957 | Consumer Willingness to Pay for Dengue Vaccine (CYD-TDV, Dengvaxia®) in Brazil; Implications for Future Pricing Considerations |
| Q36336154 | Cost-effectiveness of dengue vaccination in Yucatán, Mexico using a dynamic dengue transmission model |
| Q60050031 | Customers' preferences and willingness to pay for a future dengue vaccination: a study of the empirical evidence in Vietnam |
| Q61805479 | Dengue and chikungunya seroprevalence among Qatari nationals and immigrants residing in Qatar |
| Q38645215 | Dengue burden in India: recent trends and importance of climatic parameters |
| Q56396592 | Dengue infection in India: A systematic review and meta-analysis |
| Q59192364 | Designing a polytope for use in a broad-spectrum dengue virus vaccine |
| Q40044232 | Emerging Infections and Pertinent Infections Related to Travel for Patients with Primary Immunodeficiencies. |
| Q47192433 | Epidemiological, Serological, and Virological Features of Dengue in Nha Trang City, Vietnam |
| Q97565389 | Ethics of a partially effective dengue vaccine: Lessons from the Philippines |
| Q57069443 | Feasibility and willingness to pay for dengue vaccine in the threat of dengue fever outbreaks in Vietnam |
| Q56353070 | Forecasting the effectiveness of indoor residual spraying for reducing dengue burden |
| Q29994534 | Historical Perspectives on Flavivirus Research |
| Q54091248 | History, epidemiology and diagnostics of dengue in the American and Brazilian contexts: a review. |
| Q89971915 | Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial |
| Q56396529 | Implementing a dengue vaccination programme-who, where and how? |
| Q30250977 | In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination |
| Q38734455 | Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination |
| Q29051494 | Lack of Durable Cross-Neutralizing Antibodies Against Zika Virus from Dengue Virus Infection |
| Q41928914 | Lineage-Specific Real-Time RT-PCR for Yellow Fever Virus Outbreak Surveillance, Brazil |
| Q47548053 | Performance Evaluation of Commercial Dengue Diagnostic Tests for Early Detection of Dengue in Clinical Samples |
| Q42730622 | Phage-Displayed Peptides Selected to Bind Envelope Glycoprotein Show Antiviral Activity against Dengue Virus Serotype 2. |
| Q54260853 | Phase I Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico. |
| Q54231305 | Physiological temperatures reduce dimerization of dengue and Zika virus recombinant envelope proteins. |
| Q51145460 | Population dynamics of engineered underdominance and killer-rescue gene drives in the control of disease vectors. |
| Q59792363 | Prevalence and Risk Factors of Dengue Infection in Khanh Hoa Province, Viet Nam: A Stratified Cluster Sampling Survey |
| Q33715238 | Preventive and therapeutic challenges in combating Zika virus infection: are we getting any closer? |
| Q56475810 | Projected costs associated with school-based screening to inform deployment of Dengvaxia: Vietnam as a case study |
| Q58759739 | Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning |
| Q47400186 | Regulatory T-cells in acute dengue viral infection |
| Q52684747 | Safety issues from a Phase 3 clinical trial of a live-attenuated chimeric yellow fever tetravalent dengue vaccine. |
| Q49820319 | Seroprevalence of Dengue Antibodies in Three Urban Settings in Yucatan, Mexico |
| Q33853736 | Seroprevalence of antibodies to dengue and chikungunya viruses in Thailand |
| Q92732496 | Serostatus testing and dengue vaccine cost-benefit thresholds |
| Q41919749 | Spatial-temporal distribution of dengue and climate characteristics for two clusters in Sri Lanka from 2012 to 2016. |
| Q56881264 | Spectrum of activity testing for therapeutics against all four dengue virus serotypes in AG129 mouse models: Proof-of-concept studies with the adenosine nucleoside inhibitor NITD-008 |
| Q64359240 | Synthesis and structure-activity relationships of 3,5-disubstituted-pyrrolo[2,3- b]pyridines as inhibitors of adaptor associated kinase 1 (AAK1) with antiviral activity |
| Q57146464 | The Estimates of the Health and Economic Burden of Dengue in Vietnam |
| Q36206692 | The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study |
| Q55432397 | The US Military Commitment to Vaccine Development: A Century of Successes and Challenges. |
| Q59329635 | The acceptance and willingness to pay (WTP) for hypothetical dengue vaccine in Penang, Malaysia: a contingent valuation study |
| Q43046632 | The additional benefit of residual spraying and insecticide-treated curtains for dengue control over current best practice in Cuba: Evaluation of disease incidence in a cluster randomized trial in a low burden setting with intensive routine control |
| Q61810667 | Thioguanine-based DENV-2 NS2B/NS3 protease inhibitors: Virtual screening, synthesis, biological evaluation and molecular modelling |
| Q45880802 | Using Wolbachia for Dengue Control: Insights from Modelling |
| Q98226372 | Well-balanced immune response and protective efficacy induced by a single dose of live attenuated tetravalent dengue vaccine (KD-382) in monkeys |
| Q40047862 | Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Risks of Incomplete Immunity to Dengue Virus Revealed by Vaccination |
| Q40047872 | Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? There Is Only One True Winner |
| Q90014164 | Why are vaccines against many human viral diseases still unavailable; an historic perspective? |
Search more.